Revolution Medicines director granted stock awards

Q: What insider transaction did RVMD director Flavia Borellini report?

Director Flavia Borellini reported receiving new equity awards, including 1,191 shares of common stock as Restricted Stock Units and a stock option for 3,127 shares. These awards are compensation-related grants, not open-market purchases or sales, and increase her direct equity exposure to Revolution Medicines.

Q: How many RVMD common shares does Flavia Borellini hold after this Form 4?

After the reported grants, Flavia Borellini directly holds 26,215 shares of common stock. This total includes 1,191 Restricted Stock Units. The filing shows her updated ownership following the equity awards, giving investors a snapshot of her current direct stake in Revolution Medicines.

Q: What are the terms of Flavia Borellini’s new RVMD stock option grant?

She received a stock option for 3,127 shares of Revolution Medicines common stock with an exercise price of $162.99 per share. The option expires on June 18, 2036 and represents the right, but not the obligation, to buy shares at that fixed price.

Q: When do Flavia Borellini’s new RVMD stock options vest?

The option shares vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the Annual Meeting following the grant date. Vesting is conditioned on her continuing as a service provider under the company’s 2020 Plan until that date.

Q: What are the 1,191 RVMD shares mentioned in the Form 4 footnote?

The Form 4 states that the total includes 1,191 Restricted Stock Units. RSUs are share-based awards that typically convert into common stock upon vesting, subject to continued service and any other specified conditions in the company’s equity compensation plan.

Revolution Medicines director Flavia Borellini received new equity awards.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Revolution Medicines director Flavia Borellini received new equity awards. She was granted 1,191 shares of common stock in the form of Restricted Stock Units, increasing her direct holdings to 26,215 common shares. She also received a stock option for 3,127 shares at an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as she remains a service provider under the company’s 2020 Plan.

Insider Trade Summary

Grant/Award: 4,318 shares

Grant/Award 2 txns

Insider Borellini Flavia

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,127	$0.00	$0.00
Grant/Award	Common Stock	1,191	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 3,127 contracts (Direct); Common Stock — 26,215 shares (Direct)

Footnotes (2)

F1. Includes 1,191 Restricted Stock Units.
F2. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Key Figures

Restricted Stock Units granted: 1,191 shares Common shares held after grant: 26,215 shares Stock options granted: 3,127 options +2 more

5 metrics

Restricted Stock Units granted 1,191 shares Equity award of common stock as RSUs to director

Common shares held after grant 26,215 shares Director’s direct ownership following Form 4 transactions

Stock options granted 3,127 options New option award linked to common stock

Option exercise price $162.99 per share Strike price for the 3,127-share option grant

Option expiration date June 18, 2036 Final expiration for new stock option award

Key Terms

Restricted Stock Units, Stock Option (Right to Buy), exercise price, Service Provider, +1 more

5 terms

Restricted Stock Units financial

"Includes 1,191 Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with 3,127 shares underlying."

exercise price financial

"conversion_or_exercise_price: "162.9900" for the stock option grant."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Service Provider financial

"subject to the Reporting Person remaining a Service Provider under the 2020 Plan."

2020 Plan financial

"Service Provider (as defined in the 2020 Plan) through the vesting date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD director Flavia Borellini report?

Director Flavia Borellini reported receiving new equity awards, including 1,191 shares of common stock as Restricted Stock Units and a stock option for 3,127 shares. These awards are compensation-related grants, not open-market purchases or sales, and increase her direct equity exposure to Revolution Medicines.

How many RVMD common shares does Flavia Borellini hold after this Form 4?

After the reported grants, Flavia Borellini directly holds 26,215 shares of common stock. This total includes 1,191 Restricted Stock Units. The filing shows her updated ownership following the equity awards, giving investors a snapshot of her current direct stake in Revolution Medicines.

What are the terms of Flavia Borellini’s new RVMD stock option grant?

She received a stock option for 3,127 shares of Revolution Medicines common stock with an exercise price of $162.99 per share. The option expires on June 18, 2036 and represents the right, but not the obligation, to buy shares at that fixed price.

When do Flavia Borellini’s new RVMD stock options vest?

The option shares vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the Annual Meeting following the grant date. Vesting is conditioned on her continuing as a service provider under the company’s 2020 Plan until that date.

What are the 1,191 RVMD shares mentioned in the Form 4 footnote?

The Form 4 states that the total includes 1,191 Restricted Stock Units. RSUs are share-based awards that typically convert into common stock upon vesting, subject to continued service and any other specified conditions in the company’s equity compensation plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 05:42 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borellini Flavia

(Last)

(First)

(Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2026		A		1,191	A	$0	26,215⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$162.99	06/18/2026		A		3,127		⁽²⁾	06/18/2036	Common Stock	3,127	$0	3,127	D

Explanation of Responses:

1. Includes 1,191 Restricted Stock Units.

2. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

	/s/ Jack Anders, as Attorney-in-fact for Flavia Borellini	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR